CCDM Regulatory Requirements 4 — Questions and Answers
Question 1: What is the regulatory significance of a 'serious adverse event' (SAE) report timeline requirement under ICH E6 for sponsors?
- Sponsors must report fatal or life-threatening unexpected SAEs to the FDA within 7 calendar days (Correct answer)
- Sponsors must report all SAEs within 24 hours of awareness
- Sponsors must report SAEs to the IRB within 15 business days
- Sponsors must report all SAEs in the annual IND safety report only
Correct answer: Sponsors must report fatal or life-threatening unexpected SAEs to the FDA within 7 calendar days
ICH E6 and 21 CFR 312.32 require sponsors to report fatal or life-threatening unexpected serious adverse reactions to the FDA within 7 calendar days of awareness.
Question 2: Which component of a Clinical Study Report (CSR) is required by ICH E3 to include a comprehensive listing of all protocol deviations?
- Appendix 16.2 (Patient Data Listings)
- The Executive Summary section
- The Statistical Analysis Plan (SAP)
- Section 10 (Study Patients) (Correct answer)
Correct answer: Section 10 (Study Patients)
ICH E3 requires Section 10 of the CSR to discuss all protocol deviations, including those that affected subject eligibility, conduct, or evaluation.
Question 3: When a clinical data manager creates a Data Management Plan (DMP), which regulatory requirement makes this document essential for FDA inspections?
- It demonstrates that data handling procedures were pre-specified and followed consistently (Correct answer)
- It replaces the need for a statistical analysis plan in the submission
- It fulfills the IRB requirement for study oversight documentation
- It serves as a signed investigator agreement per 21 CFR 312.53
Correct answer: It demonstrates that data handling procedures were pre-specified and followed consistently
A DMP demonstrates to inspectors that data collection, processing, and quality control procedures were defined prospectively and consistently followed, supporting data integrity.
Question 4: Under 21 CFR Part 11, which of the following is a requirement for electronic records to be considered trustworthy by the FDA?
- Records must be accurate, reliable, and their authenticity must be readily available for inspection (Correct answer)
- Records must be printed and signed by the investigator at each visit
- Records must be stored exclusively on FDA-approved server hardware
- Records must be verified by a notary public before submission
Correct answer: Records must be accurate, reliable, and their authenticity must be readily available for inspection
21 CFR Part 11 requires that electronic records be accurate, reliable, consistent, and their authenticity, integrity, and confidentiality must be maintained and available for FDA review.
Question 5: What is the primary regulatory purpose of requiring source document verification (SDV) during clinical trial monitoring?
- To confirm that data recorded in the CRF accurately reflects the original source records (Correct answer)
- To ensure that data entry operators have proper training certifications
- To verify that the EDC system meets 21 CFR Part 11 requirements
- To confirm that the investigator has read and signed the protocol
Correct answer: To confirm that data recorded in the CRF accurately reflects the original source records
SDV ensures that data transcribed into CRFs or EDC systems accurately and completely reflects the original source data, supporting data integrity for regulatory submissions.
Question 6: According to ICH E6 R2, what is a key responsibility of the sponsor regarding the quality management system for clinical trials?
- Implementing a system that focuses on preventing and detecting errors and deviations that matter most to participant protection and data reliability (Correct answer)
- Ensuring that 100% of source data is verified at every site visit
- Providing all investigators with identical SOPs regardless of site-specific needs
- Requiring IRB approval for every data query issued to site staff
Correct answer: Implementing a system that focuses on preventing and detecting errors and deviations that matter most to participant protection and data reliability
ICH E6 R2 emphasizes a risk-proportionate quality management system focused on critical processes and data that have the most impact on participant safety and decision-making.
Question 7: In the US regulatory framework, what distinguishes a 'waiver of informed consent' from a 'waiver of informed consent documentation'?
- A waiver of documentation allows verbal consent without a written signature, while a waiver of consent allows proceeding without any consent process (Correct answer)
- A waiver of documentation eliminates all consent requirements, while a waiver of consent requires only verbal confirmation
- Both waivers eliminate the need for any subject communication about the study
- A waiver of documentation requires IRB approval, while a waiver of consent does not
Correct answer: A waiver of documentation allows verbal consent without a written signature, while a waiver of consent allows proceeding without any consent process
A waiver of documentation means consent is still obtained verbally but no signed form is required, whereas a waiver of consent means the entire informed consent process can be bypassed under specific emergency or minimal-risk conditions.
CCDM Regulatory Requirements 4
What is the regulatory significance of a 'serious adverse event' (SAE) report timeline requirement under ICH E6 for sponsors?